The UK start-up, MiNA Therapeutics, which is taking a novel approach to the development of RNA-targeted drugs by activating RNA rather han by the more conventional interference/inhibition, has raised $23m ($30m) in a series A financing led by Israel’s life sciences VC, aMoon. Existing investors also took part in the funding round.
aMoon was co-founded in 2017 by Israeli billionaire Marius Nacht (a founder of the cyber security firm, Check Point Software...






